HER2/neu Receptor Antagonist [EPC] class drugs

12 results
  • herceptin - trastuzumab injection, powder, lyophilized, for solution

    (Trastuzumab)
    Genentech, Inc.
    Herceptin treats HER2-overexpressing breast cancer (adjuvant and metastatic) and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in adults. Used in combination chemotherapy regimens or as a single agent. Requires FDA-approved companion diagnostic for patient selection.
  • herceptin hylecta - trastuzumab and hyaluronidase - oysk injection, solution

    (Trastuzumab And Hyaluronidase-Oysk)
    Genentech, Inc.
    Herceptin Hylecta (trastuzumab/hyaluronidase) treats HER2-overexpressing breast cancer in adults. Indicated for adjuvant treatment of node-positive or high-risk node-negative breast cancer, and for metastatic breast cancer — first-line with paclitaxel or as a single agent after prior chemotherapy.
  • margenza - margetuximab - cmkb injection, solution, concentrate

    (Margetuximab-Cmkb)
    Macrogenics, Inc
    Margenza is used with chemotherapy to treat adults with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, with at least one for metastatic disease.
  • perjeta - pertuzumab injection, solution, concentrate

    (Pertuzumab)
    Genentech, Inc.
    Perjeta is used with trastuzumab and chemotherapy to treat HER2-positive breast cancer in adults. Indicated for metastatic breast cancer without prior anti-HER2 therapy, neoadjuvant treatment of locally advanced or early-stage breast cancer, and adjuvant treatment of early breast cancer at high risk of recurrence.